Frank Kondrad - Neurobo Pharmaceuticals VP Devel
| NRBODelisted Stock | USD 1.89 0.11 5.50% |
Insider
Frank Kondrad is VP Devel of Neurobo Pharmaceuticals
| Phone | 857 702 9600 |
| Web | https://www.neurobopharma.com |
Neurobo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7435) % which means that it has lost $0.7435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6076) %, meaning that it created substantial loss on money invested by shareholders. Neurobo Pharmaceuticals' management efficiency ratios could be used to measure how well Neurobo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Neurobo Pharmaceuticals currently holds 203 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Neurobo Pharmaceuticals has a current ratio of 7.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neurobo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Tomasz George | Virax Biolabs Group | 40 | |
| Jason Assad | 180 Life Sciences | N/A | |
| James Rolke | Revelation Biosciences | 56 | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Jonathan Rothbard | 180 Life Sciences | 71 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| John Cini | Sonnet Biotherapeutics Holdings | 73 | |
| MD MBA | Kiora Pharmaceuticals | 52 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 36 | |
| Brian Strem | Kiora Pharmaceuticals | 46 | |
| Steen Knudsen | Allarity Therapeutics | 64 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| James JD | Allarity Therapeutics | 55 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Quan Vu | 180 Life Sciences | 52 | |
Management Performance
| Return On Equity | -1.61 | |||
| Return On Asset | -0.74 |
Neurobo Pharmaceuticals Leadership Team
Elected by the shareholders, the Neurobo Pharmaceuticals' board of directors comprises two types of representatives: Neurobo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurobo. The board's role is to monitor Neurobo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Neurobo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurobo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD BCPS, VP Operations | ||
| Marshall Woodworth, Principal CFO | ||
| HyungHeon Kim, President CEO | ||
| Robert Homolka, Senior Operations | ||
| Ben MD, CEO Pres | ||
| Frank Kondrad, VP Devel | ||
| MiKyung Kim, Chief Officer |
Neurobo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurobo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.61 | |||
| Return On Asset | -0.74 | |||
| Current Valuation | (1.18 M) | |||
| Shares Outstanding | 8.62 M | |||
| Shares Owned By Insiders | 65.23 % | |||
| Shares Owned By Institutions | 12.71 % | |||
| Number Of Shares Shorted | 34.27 K | |||
| Price To Earning | (1.44) X | |||
| Price To Book | 1.57 X | |||
| Revenue | 7 K |
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Neurobo Stock
| 0.81 | MMM | 3M Company | PairCorr |
| 0.71 | BA | Boeing | PairCorr |
| 0.67 | JPM | JPMorgan Chase | PairCorr |
| 0.67 | GE | GE Aerospace | PairCorr |
| 0.66 | CSCO | Cisco Systems | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |